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Photo: Rana Hajjeh, MD and Marsha Houston with PneumoniaFighters! in 
Washington, DC on World Pneumonia Day. PnemoniaFighters! distributed 
information at metro transit stations throughout Washington, DC, in Geneva, 
Switzerland and at CDC to call public attention to the need to prevent this 
disease that claims the lives of 1.6 million children younger than age 5 
every year. CDC is a lead partner for coordinating this global activity.
PedvaxHIB® is fully available again in the U.S. for routine vaccination after a nationwide shortage. During the 
shortage, Division of Bacterial Diseases (DBD) staff closely monitor for increased cases of Hib disease and make 
temporary vaccine recommendations.
The meningococcal conjugate vaccine, Menveo®, is licensed by FDA on February 22. DBD staff  
contributed data and expertise to the first meningococcal conjugate vaccine  
recommendations in 2005, which Menveo® will follow. See the March 12 issue of MMWR  
for more details.
The 13-valent pneumococcal conjugate vaccine (PCV13) is licensed by FDA on  
February 24. On that same day, the Advisory Committee on Immunization Practices (ACIP) 
votes to recommend PCV13. DBD staff contribute data and expertise to help shape the  
vaccine recommendations that ACIP discusses and votes on. Refer to the March 12 issue  
of MMWR for more details. 
MenAfriVac™ (meningococcal serogroup A conjugate vaccine), manufactured by Serum 
Institute of India Ltd., receives formal approval on January 24 and is now being  
manufactured at scale. Priced at just US$ 0.40 per dose, MenAfriVac™ is expected to  
prevent 123,000 deaths 
over the next ten years 
across the meningitis belt. 
See Summer/Fall DBD 
Bulletin for more  
information.  
With American Recovery and Reinvestment 
Act (Recovery Act) funds, the Association of 
Public Health Laboratories in collaboration with 
DBD, develops and conducts webinars on  
bacterial vaccine-preventable pathogens,  
including pertussis (454 participants) and  
pneumococcus (252 participants). This is  
followed up with a bacterial wet-lab training at 
CDC in October, hosted by DBD laboratorians.
Legionella is proposed to be added to Active 
Bacterial Core surveillance (ABCs). Over the next 
few months, several ABCs sites agree to  
participate. 
Photo: A vial of 
MenAfriVac™, 
manufactured by  
Serum Institute  
of India, Ltd.
Photo: State and local health department workshop 
participants prepare and pipet samples, primers, and probes 
for PCR plate setup in a biological safety cabinet in the CDC 
















This bulletin reviews some of the 
major activities of the division, as 
well as major events that have 
relevance to our work. It’s hard to 
believe another year just passed 
by, but it’s also harder to imagine 
that so much work can be done 
in one year! We have helped with 
controlling multiple outbreaks of 
pertussis and continue to have 
people in the field right now in 
three states. Significant impact on 
policy has been made by providing 
support to multiple ACIP decisions 
and publishing updated  
recommendations for anthrax 
vaccine and revised guidelines 
for group B Strep prevention. We 
started a major neonatal sepsis 
etiology study in south Asia and 
trained laboratorians all over the 
world to better diagnose vaccine- 
preventable bacterial diseases. 
World Pneumonia and Meningitis 
Days and Get Smart About 
Antibiotics Week were celebrated. 
The division has been part of the 
accelerated introduction of  
pneumococcal vaccines in  
developing countries, and just 
this month, the launch of the long 
awaited meningococcal A  
conjugate vaccine in West Africa. 
I just came back from Burkina 
Faso, where the meningococcal 
vaccine was officially launched. 
Watching the lines of people 
queuing up with their children to 
receive the vaccine was an  
amazing and most rewarding 
sight, but even more rewarding 
is knowing that our division has 
contributed significantly to bringing 
this vaccine to the meningitis belt 
countries, and saving thousands 
of lives from succumbing to a  
disease that’s devastating to  
people, families and countries.
I would like to thank you for all 
your hard work that made such 
accomplishments possible and 
wish you very happy and  
restful holidays. We will need all 
our energy when we’re back!
             Rana
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ulletinThree Legionellosis webinars are conducted as part of the Water, Sanitation, and Hygiene (WASH) webinar series. A partnership between DBD and the Waterborne Disease Prevention Branch, this three-part series focuses on outbreak investigation, detailing the major steps in investigating a 
Legionellosis outbreak. An estimated 300 professionals in state and local public health departments in 36 states participate in the webinars.  
Tdap and meningococcal conjugate vaccine recommendations are updated by ACIP. It is now recommended 
that adults 65 years and older can receive Tdap, especially if around young infants; there is no recommended 
minimum interval between Tdap and last Td; and 7 to 9 year olds can get Tdap if not up-to-date. It is now 
recommended that adolescents who receive a dose of the meningococcal conjugate vaccine at age 11 or 12 years 
should get a booster dose at age 16 years. Final policy notes are on track to be published in MMWR in December.
New Group B Strep prevention guidelines are published by DBD, replacing the 2002 guidelines. These 
2010 guidelines were developed using an evidence-based approach in collaboration with several professional 
associations. New resources and a website are launched at www.cdc.gov/groupBstrep. Refer to the November 19 
issue of MMWR for more details.
An External Review of DBD’s 
Vaccinology Laboratories is held 
in October. Nationally recognized 
vaccinology experts make 
recommendations for future operational 
activities.
The 2nd annual World Pneumonia 
Day is November 12. DBD provides technical assistance to organize 
worldwide activities: Premiere showing of the Photoshare World Pneumonia 
Photo Exhibition at the New York Times Center during the United Nations 
Summit on the Millennium Development Goals and introducing the 
PneumoniaFighters! at DC transit stations, in Geneva, Switzerland, and at 
CDC Atlanta. The World Pneumonia photo exhibition is on display at the 
CDC Public Health Library and Information Center during November.  
Photo: MMWR cover for the 
Prevention of Perinatal Group B 
Streptococcal Disease, Revised 
Guidelines from CDC, 2010
Photo: DBD epidemiology, laboratory and statistics staff at CDC 
Atlanta with the PneumoniaFighter! on World Pneumonia Day.
The 3rd annual Get Smart About Antibiotics Week is November 15-21. DBD partners with local health 
departments, non-profit partners and for-profit partners to reach millions of people. Messages and 
resources for healthcare settings from CDC’s Get Smart for Healthcare program are included for the first 
time. November 18 marks the first year of international collaboration, coinciding with European Antibiotic 
Awareness Day and an observance day in Canada. 
The “New Vaccines for Global Health” meeting is held in London as part of the 350th Anniversary of the 
Royal Society. One of the invited international vaccine experts, DBD’s director presents on “Introducing new 
vaccines in developing countries: 
Challenges of decision making 
and lessons learned from the Hib 
vaccine experience.”
DBD responds to pertussis 
outbreaks across the country 
with Epi-AIDS in California, 
Minnesota and Ohio. In California,
multiple teams of CDC staff collec
patient data by visiting healthcare 
provider offices. In Minnesota, 
a team collects vaccine history 
and creates a massive database 
to analyze; DBD statisticians 
are integrally involved. In Ohio, 
 
t 
the CDC team works with the state and local health departments to better 
understand the outbreak. 
In 2010, DBD initiates case-based surveillance for laboratory-confirmed 
meningitis and completes enrollment of 25,000 subjects for the meningococcal 
carriage study in Burkina Faso.
Photo: Emory University’s Keith 
Klugman, MD, PhD and Rana Hajjeh, 
MD attending the 350th Anniversary of 
the Royal Society
Photo: Isolates of Neisseria meningitidis and DNA specimens collected 
in Burkina Faso were shipped to the CDC Meningitis Laboratory in 
November. DBD Lab staff give a proud “thumbs up” as they prepare to 
start a series of lab tests as part of CDC’s ongoing technical support for 
meningitis research and surveillance activities in sub Saharan Africa. 
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The 2nd annual World Meningitis Day takes place on April 24. On April 20, the Meningitis and 
Vaccine Preventable Diseases Branch is honored at the 2010 National Meningitis Association Gala, 
Give Kids a Shot! in New York City. The National Meningitis Association educates families, medical 
professionals and others about bacterial meningitis and prevention approaches to the disease.
The PCV13 vaccine efficacy study starts — supported with funding from the Recovery Act. 
This study will enroll patients with pneumococcal disease (who have received PCV13) caused by 
vaccine-preventable serotypes to determine the vaccine’s percent efficacy.
A pertussis epidemic is declared by the California Department of Public Health and DBD 
responds with multiple Epi-AIDS, ethnic media roundtables, a radio media tour, press interviews 
and other technical support. See Summer/Fall DBD Bulletin for more information.  
A pilot test on the World Health Organization (WHO) assessment tool for invasive bacterial 
diseases is conducted by DBD staff in Latvia.
MenAfriVac™ is prequalified by WHO in June. Infant pre-licensure studies for which DBD is 
testing sera are on track for completion in 2011.
Photo: Amanda Faulkner records a voiceover for a 
“how to” video on specimen collection for pertussis 
testing, one of the new pertussis tools created in 2010.
Photo: Gloria Carvalho, PhD in a pre-assessment meeting with colleagues 
from the Infectology Center of Latvia, familiarizes them with the assessment 
tool for invasive bacterial diseases.
Relevant Major Events
DBD plays a key role in taking MenAfriVac™ from development 
to public health availability. The vaccine is introduced nationwide 
in Burkina Faso in December with introduction campaigns 
scheduled for Niger and Mali by the end of the year.
Bill and Melinda Gates announce a $10 billion 10 year 
committement to help research, develop and deliver vaccines for 
the world’s poorest countries.
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Updated anthrax vaccine adsorbed (AVA) recommendations are published. 
DBD epidemiologists lead the Working Group. Laboratorians and statisticians 
contribute data and expertise, including implementing and analyzing the clinical 
trials to help shape the vaccine recommendations that ACIP discussed and voted 
on in 2009. See the July 23 issue of MMWR for more details.
The International Conference on Emerging Infectious Diseases is held July 
11-14 in Atlanta. DBD’s director is the co-chair of the scientific committee and 
DBD’s associate director for science is a member of the committee. Many staff 
from DBD attend and present at the conference. See abstracts at www.iceid.org.
Pilot safety introduction campaigns of MenAfriVac™ are completed this 
fall and find no concerning safety signals. A team from DBD is on the ground in 
Burkina Faso for the official launch of the largest meningitis vaccine campaign in 
history. 
Photo: In Burkina Faso in December, a young boy receives 
MenAfriVac™, while others line up for their turn. By mid-
December, 6 million people are vaccinated.
Photo: While EIS Officer George Nelson is in Quetzaltenango, 
Guatemala, pharmacists use PDAs to complete surveys about 
antibiotic prescribing and dispensing practices. This project 
is aiming to decrease inappropriate antibiotic use throughout 
Guatemala.
Get Smart Goes Global:  DBD introduces a program in Egypt and 
Guatemala. See the 2nd Quarter CDC Global Health E-Brief for 
more information.
The ANISA (Aetiology of Neonatal Sepsis in South Asia) study 
is funded by the Bill & Melinda Gates Foundation. Taking place in 
three countries in South Asia (Bangladesh, India and Pakistan) that 
account for more than a third of all neonatal deaths, DBD is a co-PI 
of the study that will improve neonatal survival in the region and 
beyond by describing aetiology of community acquired young infant 
infections, antibiotic sensitivity of bacterial pathogens, and risk fac-
tors for infection. Staff throughout NCIRD are involved in the study.
DBD 2010 FAST FACTS
11 Epi-AIDS







10 International Lab Trainings
2CDC Connects Articles
2CDC Global Health E-Briefs
3 Websites
4 New EISOs
